

## DAFTAR PUSTAKA

1. Karam JH, Forsham. Hormon-hormon pankreas dan diabetes melitus. In: Greenspan FS, Baxter, editors. Endokrinologi dasar dan klinik. 4th ed. Jakarta: EGC; 2000.
2. German MS, Masharani. Pancreatic hormones and diabetes mellitus. In: Gardner DG, Shoback D, editors. Greenspan's basic and clinical endocrinology. 8th ed. America: McGraw Hill, Companies; 2004. p. 661-747.
3. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms. *Diabet Care* 2010;33(2):442-9.
4. PERKENI, editor. Konsensus : pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2011. Jakarta: PERKENI; 2011.
5. Meydani PYD. Faktor-faktor yang berhubungan dengan upaya pencegahan komplikasi DM oleh pasien DM di poliklinik khusus penyakit dalam RSUP dr. M. Djamil Padang. FK Andalas Padang 2011.
6. Supriyono M, Suharyo, Sugiri. Faktor-faktor risiko yang berpengaruh terhadap kejadian penyakit jantung koroner pada kelompok usia kurang 45 tahun (studi kasus di RSUP dr Kariadi dan RS Telogorejo). Semarang: UNDIP; 2008.
7. Johnstone MT, Veves A. Diabetes and cardiovascular disease. 2nd ed. New Jersey: Humana Press; 2005.
8. Ismail H, Hanafiah M, Saadiah S, Tahir A, Huda Z, Yunus M. Control of glycosylated haemoglobin (HbA1c) among type 2 diabetes mellitus patients attending an urban health clinic in Malaysia. *MHSJ* 2011;9:58-65.
9. Josten S, Mutmainnah, Hardjoeno. Profil lipid penderita diabetes melitus tipe 2. *IJCPML*;13(1):20-2.

10. Soegondo S. Farmakoterapi pada pengendalian glikemia DM tipe 2. In: Sudoyo AW, Setiyohadi, Alwi I, Simandibrata M, Setiati, editors. Buku ajar: ilmu penyakit dalam. 5th ed. Jakarta: InternaPublishing; 2009. p. 1884-90.
11. Jabeen F, Rizvi HA, Aziz F, Akhtar Y. Effect of glycemc control on lipid profile, platelet indices and antioxidant enzymes ( catalase and superoxide dismutase ) activities in type 2 diabetics. IJAR 2013;1(7):207-15.
12. Momin AA, Banker MP, Bhoite GM. Glycosylated (HbA1C) : association with dyslipidemia and predictor of cardiovascular diseases in type 2 diabetes mellitus patients. IJHSR 2013;3(8):40-6.
13. Hessin SS, Abdrabo EA. Measurement of plasma triglyceride and total cholesterol in sudanese patients with controlled and uncontrolled type 2 diabetes. IJIAR 2014;2(2):47-50.
14. Holvoet P, de Keyzer D, Jacobs D. Oxidized LDL and the metabolic syndtome. Future lipidol 2008;3(6):637-49.
15. Ekawati ER. Hubungan kadar glukosa darah terhadap hipertrigliserida pada penderita diabetes mellitus. Seminar nasional kimia UNESA Surabaya 2012.
16. Cleland SJ. Cardiovascular risk in double diabetes mellitus when two worlds collide. Nat.Rev Endocrinol 2012;8:476-85.
17. Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, *et al.* Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. JCL 2013;7(4):233-9.
18. Pushparaj JL, Kirubakaran S. HbA1C as a predictor of lipid profile in type 2 diabetic patients. JEMDS 2014;3(12):3157-65.
19. Little RR, Sacks DB. HbA1C : How do we measure it and what does it mean. Curr Opin Endocrinol Diabetes Obes 2009;16:113-8.
20. Christy AL, Manjrekar PA, Babu RP, Hegde A. Influence of iron deficiency anemia on hemoglobin A1C levels in diabetic individuals with controlled plasma glucose levels. IBJ 2014;18(2):88-93.

21. Charitha, Senghor A, Shivashekar M, William E. Glycated Hemoglobin as a dual marker: in control of glycemia status and diabetic dyslipidemia. *IJPCR* 2013;5(3):111-3.
22. Sasisekhar TVD, Shabana S. Can HbA1c act as a surrogate marker for cardiovascular risk. *JDMS* 2013;3(4):39-43.
23. Singh P, Arumalla VK, Rajagopalan B. Comparison of lipid profile between controlled and uncontrolled type 2 diabetic subjects. *JMHS* 2013;2(4):69-72
24. Senghor A, William E. Correlation of HbA1C and non HDL cholesterol to assess diabetic dyslipidemia. *IJRSR* 2014;5(5):931-3.
25. Pujari SS. HbA1C as marker of dyslipidemia in type 2 diabetes mellitus patients. *SJAMS* 2013;1(6):728-31.
26. Bodhe C, Jankar D, Bhutada T, Patwardhan M, Patwardhan MV. HbA1C: predictor of dyslipidemia and atherogenicity in diabetes mellitus. *IJBMS* 2011;2(5):278-82.
27. Songa RM. Lipid profile in type 2 DM with obesity. *BOPAMS* 2013;1(2):132-8.
28. Ugwu CE, Ezeanyika LUS, Daikwo MA, Amana R. Lipid profile of diabetic patients attending Nigerian National Petroleum Corporation Clinic, Abuja. *AJBR* 2009;3(3):66-9.
29. Otamere HO, Aloamaka CP, Okokhere PO, Adisa WA. Lipid profile in diabetes mellitus; What impact has age and duration. *BJPT* 2011;2(3):135-7.
30. Siddiqui IA, Laxmikanth B, Mariya, Rao R. Lipid indices in type II diabetes mellitus and their association with macro and micro vascular complications. *IJMRHS* 2012;2(1):87-92.
31. Khan HA. Clinical significance of HbA1C as a marker of circulating lipids in male and female type 2 diabetic patients. *Acta Diabetol* 2007;2:1-5

32. Loei GSC, Pandelaki K, Mandang V. Hubungan kadar HbA1C dengan profil lipid pada penderita DM tipe 2 di poliklinik endokrin dan metabolic RSUP Prof. dr. R. D. Kandou Manado. IPD FK Sam Ratulangi Manado 2013.
33. Hasan H, Isnanta R. Hubungan mikroalbuminuria dengan penyakit jantung koroner. Departemen Kardiologi dan Kedokteran vaskuler FK-USU/RS H. Adam Malik Medan. MKN 2006;39(3):239-42.
34. Garg N, Agrawal YB, Gupta S. A study of lipid profile levels in diabetics and non-diabetics taking TC/HDL ratio consideration. JIACM 2014;15(3-4):192-5.
35. Gomes MB, Giannella-Neto, Faria M, Tambascia M, Fonseca RM, Rea R et al. Estimating cardiovascular risk in patients with type 2 diabetes: a national multicenter study in Brazil. Diabetol Metab Syndr 2009;1(22):1-7.
36. Wilson PWF. Lipids and vascular disease: a framinghan perspective. Global Heart 2013;8(1):25-33.
37. Chan DC, Watts. Apolipoprotein as marker and managers of coronary risk. QJ Med 2006;99:277-87.
38. Mallick AK, Maradi R, Joshi VR, Bhat G. A study on apo B100/apo A-I ratio in uncontrolled type 2 diabetes mellitus. IJABPT 2011;2(1):379-84.
39. Ali MK, Narayan KMV, Tandon N. Diabetes and coronary heart disease: current perspective. IJMR 2010;132:584-97.
40. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV et al. Diabetes and cardiovascular disease a statement for healthcare professionals from the American heart association. Circulation 1999;100:1134-45.
41. Meenu J, Jayendrasinh J, Neeta M. Correlation between HbA1C values and lipid profile in type 2 diabetes mellitus. IJBAP ;2(1):47-50.
42. Chiha M, Njeim M, Chedrawy EG. Diabetes and coronary heart disease: a risk factor for the global epidemic. IJH 2012:1-7.

43. Tripathi BK, Srivastava AK. Diabetes mellitus : complications and therapeutics. *MSM* 2006;12(7):130-47.
44. Bartels DW, Davidson MH, Gong WC. Type 2 diabetes and CV cardiovascular disease: reducing the risk. *JMCP* 2007;13(2):1-15.
45. Khawlani AA, Atef ZA, Al-Ansi. Macrovascular complications and their associated risk factor in type 2 diabetic patients in Sana city Yemen. *EMHJ* 2010;16(8):851-8.
46. Sungkar MA. Diagnosis dan stratifikasi risiko sindroma koroner akut. In: Sungkar MA, Rifqi S, editors. *One day course: penanganan sindroma koroner akut secara paripurna*. Semarang: PERKI cab Semarang.
47. Herminingsih S, Uddin I, Tanuwidjojo. Patogenesis penyakit kardiovaskuler pada diabetes melitus. In: Darmono, Suhartono T, Pemayun TGD, Padmomartono FS, editors. *Naskah lengkap: diabetes melitus ditinjau dari berbagai aspek penyakit dalam, dalam rangka purna tugas prof dr RJ Djokomoeljanto*. Semarang: UNDIP; 2007. p. 245-56.
48. Strom JB, Libby P. Atherosclerosis. In: Lilly LS, editor. *Pathophysiology of heart disease*. 5th ed. Philadelphia: William L, Wilkins; 2011. p. 113-34.
49. Djokomoeljanto. Neuropati diabetik. In: Darmono, Suhartono T, Pemayun TGD, Padmomartono FS, editors. *Naskah lengkap : diabetes melitus ditinjau dari berbagai aspek penyakit dalam, dalam rangka purna tugas prof dr RJ Djokomoeljanto*. Semarang: UNDIP; 2007. p. 1-14.
50. Baraas F. Kardiologi molekuler radikal bebas: disfungsi endotel, aterosklerosis, antioksidan, latihan fisik dan rehabilitasi jantung. Jakarta. *Kardia Igratama*. 2006. p. 447.
51. Hadi HAR, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. *Vasc Health Risk Manag* 2007;3(6):853-76.
52. Peppas M, Vlassara H. Advanced glycation end products and diabetic complications: a general overview. *Hormones* 2005;4(1):28-37.

53. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. *Cardio diabet* 2002;1:1-10.
54. Oliveira MIA, Souza EM, Pedrosa FDO, Rea RR, Alves ADSC, Picheth G, et al. RAGE receptor and its soluble isoforms in diabetes mellitus complications. *J Bras Patol Med Lab* 2013;49(2):97-108.
55. Creager MA, Lüscher TF, Cosentino F, Becman JA. Diabetes and vascular disease pathophysiology, clinical consequences, and medical therapy: Part I. *Circulation* 2003;108:1527-32.
56. Buse JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. *Williams textbook of endocrinology*. 11th ed. Canada: Elsevier; 2008. p. 1329-89.
57. Suryaatmadja M. Standarisasi dan harmonisasi pemeriksaan HbA1C. In: Oesman editor. *Pendidikan berkesinambungan Patologi Klinik* 2010. Jakarta: Patologi Klinik FK UI; 2010. p. 92-104.
58. Sheikh SA, Baig JA, Iqbal T, Kazmi T, Baig M, Husain SS. Prevalence of microalbuminuria with relation to glycemic control in type 2 diabetic patients in Karachi. *J Ayub Med Coll Abbottabad* 2009;21(3):83-7.
59. Kurnianingsih S, Widyastuti P, Cahyaningrum R, Rahayu S. Pedoman pemeriksaan laboratorium dan diagnostik. In: Kapoh RP editor. *Laboratory and diagnostic tests with nursing implications*. Kee JL. 6th ed. Jakarta: EGC; 2008.
60. Chandalia HB, Krishnaswamy PR. Glycated hemoglobin. *Curr Sci* 2002 ;83(12):1522-32.
61. Thakur S, Chauhan V, Negi RC. Role of HbA1C in Diabetes Mellitus. *JIACM* 2009;10(2):52-4.
62. Nitin S. HbA1C and factors other than diabetes mellitus affecting it. *Singapore Med J* 2010;51(8): 616-22.

63. Yamagishi SI, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. *Curr Diabetes Rev* 2005;1:93-106.
64. Sinha N, Mishra TK, Singh T, Gupta N. Effect of iron deficiency anemia on hemoglobin A1C levels. *Ann Lab Med* 2012;32:17-22.
65. Chu CH, Wang MC, Sun TH, Lee JK, Lam HC. Very low HbA1C values patient with clinical silent hemoglobin variant (hemoglobin J)-a case report. *J Intern Med Taiwan* 2007;18:45-50.
66. Ford ES, Cowie CC, Chaoyang, Handelsman Y, Bloomgarden. Iron deficiency anemia, non iron deficiency anemia and HbA1C among adults in the US. *J Diab* 2011;3:67-73.
67. Suryaatmadja M. Peran pemeriksaan kadar HbA1C untuk diagnosis pradiabetes. In: Timan IS, Wulandari D, editors. Pendidikan berkesinambungan Patologi Klinik 2013. Jakarta: Patologi Klinik FK UI; 2013. p. 57-70.
68. Frida ME, Diah MI. Pemeriksaan HbA1C secara ion exchange HPLC. Surakarta: Patologi Klinik FK UNS; 2012.
69. Banerjee. HbA1C result, does it depend upon the testing method. *JAPI* 2014;62:9-12.
70. Adam JMF. Dislipidemia. Dalam: Sudoyo AW, Setiyohadi, Alwi I, Simandibrata M, Setiati, editors. Buku ajar ilmu penyakit dalam. 5th ed. Jakarta: InternalPublishing; 2009. p. 1984-92.
71. Anonim. Pengertian kolester. Available from: URL: <http://sulegratis.blogspot.com/2012/12/pengertian-kolesterol.html> Cited 2014 Sep 20.
72. Burts C, Ashwood E, Bruns D. *Tiets textbook of clinical chemistry and molecular diagnostic*. 5th ed. United State of America: Elsevier saunders; 2012 p. 744.

73. Nugroho HSW. Metabolisme lipid. Available from: URL: [Zaifbio.wordpress.com/2010/06/02/metabolisme-lipid](http://Zaifbio.wordpress.com/2010/06/02/metabolisme-lipid). Cited 2013 Aug 15.
74. Tomkin GH, Owens D. LDL as a cause of atherosclerosis. *Atheroscler Thromb J* 2012;5:13-21.
75. Anonim. Lipoproteins: Lipid Digestion & Transport. Available from: URL:<https://www.rpi.edu/dept/bcbp/molbiochem/MBWeb/mb2/part1/lipoprot.htm>. Cited 2014 Oct 2.
76. Raja RP, Jayarama N, Shashidhar KN. Association among HbA1C and lipid profile in kolar type 2 diabetic population. *JPSI* 2013;2(6):10-2.
77. Berneis K, Rizzo M. LDL size : does it matter? In mini review. *Swiss Med Wkly* 2004;134:720-4.
78. Suhartono T. Dislipidemia pada diabetes melitus. In: Darmono, Suhartono T, Pemayun TGD, Padmomartono FS, editors. Naskah lengkap : diabetes melitus ditinjau dari berbagai aspek penyakit dalam, dalam rangka purna tugas prof dr RJ Djokomoeljanto. Semarang: UNDIP; 2007. p. 31-50.
79. Zylbeari L, Zylberai G, Bexheti Z. Concentration of apolipoprotein B100 (Apo B100) and lipoprotein a (Lpa) at patients with diabetes mellitus. *IJSER* 2014;5(11):103-16.
80. Dixon JL, Biddle J, Lo CM, Stoops JD, Li H, Sakata N, Philip TE. Apolipoprotein B is synthesized in selected human non-hepatic cell lines but not processed into mature lipoprotein. *J Histochem Cytochem* 2002;50(5):629-39.
81. Ramjee V, Sperling LS, Jacobson TA. Non high density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification. *J Am Coll Cardiol* 2011;58(5):457-63.
82. Segrest JP, Jones MK, Loof HD, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. *J. Lipid Res* 2001;42:1346-66.

83. Fisher WR, Zech LA, Stacpoole PW. Apo B Metabolism in familial hypercholesterolemia inconsistencies with the LDL receptor paradigm. *Atheroscler Thromb* 2015;14(4):501-10.
84. Olofsson SO, Boren J. Apolipoprotein B secretory regulation by degradation. *Atheroscler Thromb Vasc Biol* 2012;32:1334-8.
85. Kwiterovich PO. Lipoprotein Heterogeneity: Diagnostic and therapeutic implications. *Am J Cardiol* 2002;90(8):1-10.
86. Wallach J. Interpretation of diagnostic tests. 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 41.
87. Pasca.unand. Hubungan glycosylated haemoglobin terhadap kadar adiponektin dan kadar trigliserida pada diabetes mellitus tipe 2. Available from: URL:Pasca.unand.ac.id/ad/wp-content/uploads/2011/09/. Cited 2014 Sep 20.
88. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. *Am J Cardiol* 1999;83:25-9.
89. Clare-Salzler MJ, Crawford JM, Kumar V. Pankreas. In: Kumar V, Citran RS, Robbins SL, editors. Robbins basic pathology. 7th ed. Jakarta: EGC; 2007.
90. Tomkin GH. Hyperglycaemia: the relation to dyslipidaemia and atherosclerosis. *Ir J Med Sci* ;171(3);161-4.
91. Isoma B. Chronic diabetic complication in clinically, immunologically and genetically defined subgroups. Helsinki 2001. p 15.
92. Prabhavathi K, Kunikullaya K, Goturu J. Glycosylated haemoglobin (HbA1C) a marker of circulating lipids in type 2 diabetic patients. *Curr Diabetes Rev* 2014;8(2):20-3.
93. Wang X, Bucala R, Milne R. Epitopes close to the apolipoprotein B low density lipoprotein receptor binding site are modified by advanced glycation end products. *Med Scien* 2008;95:7643-7.

94. Sastroasmoro S. Dasar-dasar metodologi penelitian klinis. 3rd ed. Jakarta: Sagung Seto; 2007.
95. Dahlan MS. Seri evidence based medicine : besar sampel dalam penelitian kedokteran kesehatan. Jakarta: PT ARKANS; 2006. p. 25, 67.
96. Hastono SP. Basic data analysis for health research training: analisis data kesehatan. Depok: FKM UI; 2007.
97. Yuliani F, Oenzil F, Iryani D. Hubungan berbagai faktor risiko terhadap kejadian penyakit jantung koroner pada penderita diabetes melitus tipe 2. JKA 2004;3(1):37-40.
98. Tarcin O, Uluganyan M, Tartan Z, Yekeler I. Glycemic profiles and their diagnostic value among inpatients in a cardiology clinic. Endocrinol Metab Synd 2012;5:1-5.
99. McDermott RA, McCulloch B, Li M. Glycaemia and albuminuria as predictors of coronary heart disease in Aboriginal and Torres Strait Islander adults: a north Queensland cohort. MJA 2011;194:514-8.
100. Singh G, Kumar A. Relationship among HbA1C and lipid profile in Punjabi type 2 diabetic population. JESP 2011;7(2):99-102.
101. Vinodmahato R, Gyawali P, Raut PP, Regmi P, Singh KP, Pandeya D et al. Association between glycaemi control and serum lipid profil in type 2 diabetic patients: Glycated haemoglobin as adual biomarker. Biomed Research 2011;22(3):375-80.
102. Samatha P, Prabodh S, Chowdar NVS, Shekhara. Glycated hemoglobin and serum lipid profile associations in type 2 diabetes Mellitus patients. JPBSMS 2012;17(12):1-4.
103. Yathish TR, Annamalai N, Shankar V. Association of low density lipoprotein levels and glycaemic control in type 2 diabetes mellitus. Electron Physician 2010;(2):24-32.

104. Reddy R, Jayarama N, Shashidhar KN. Association among Hba1C and lipid profile in kolar type 2 diabetic population. JPSI 2013;2(6):10-12.
105. Aboelela MI, Elmajeed ADA, Elmaksoud HA, Sayed AA. A study on apo B/apo A1 ratio as a predictive parameter for assessment of CAD risk in uncontrolled type 2 egyptian diabetic patients. EJHM 2014;54:62-70.
106. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I : risk indicator of coronary heart disease and targets for lipid modifying therapy. J Intern Med 2004;255:188-205.